Risk Warning & Pitfall Avoidance: Avoid Fake Glucagon Kits – Check Certification Documents
Abstract: Counterfeit glucagon kits pose severe risks to diabetic patients. This analysis reviews certification documents (e.g., FDA, EMA) to distinguish genuine from fake products. Market trends show rising demand for stable, room-temperature-stable glucagon analogs. Brand comparison (e.g., Eli Lilly vs. Xeris) highlights differences in formulation (liquid vs. lyophilized), shelf life, and injection device ergonomics. Technical advantages include rapid onset; drawbacks include cost and storage sensitivity. Product parameters (purity >98%, potency 1 mg/mL) and logistics (cold chain compliance) are critical. Industry data indicates 12% CAGR (2023–2030). Selection tips: verify GMP factory audits, batch certificates, and third-party lab reports.